$17.32
-1.28 (-6.88%)
Open$18.55
Previous Close$18.60
Day High$18.61
Day Low$16.83
52W High$28.29
52W Low$11.30
Volume—
Avg Volume29.4K
Market Cap55.38M
P/E Ratio—
EPS$-18.93
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-28.5% upside
Current
$17.32
$17.32
Target
$12.39
$12.39
$7.78
$12.39 avg
$16.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 17.14M | 4.59M | 4.05M |
| Net Income | -22,051,712 | -196,564 | -196,089 |
| Profit Margin | -128.7% | -4.3% | -4.8% |
| EBITDA | -22,108,262 | -265,994 | -241,454 |
| Free Cash Flow | — | -252,687 | -239,821 |
| Rev Growth | — | +16.2% | +0.5% |
| Debt/Equity | 0.20 | 1.06 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |